Amercian Society of Nephrology (ASN)

Targeting αvβ8 Integrin Improves Renal Function Through Local Inhibition of TGF-β Activationn

Integrin aVb8/TGF-b Activation in Kidney Is Associated with Renal Function Deterioration and Can Be Monitored in Urine

Lipid Metabolic Profiling of Ex Vivo Isolated Glomeruli as a Screening Platform for Modelling Glomerular Metabolic Dysfunction During Renal Disease

Human iPSC-Derived Kidney Micro-Organoids for High-Throughput Disease Modelling in Drug Discovery

Using Clustering to Facilitate Gene-Based Rare-Variant Collapsing for a Diverse Cohort of FSGS Patients

Artificial Intelligence-Driven Target Identification in CKD

Systematic In Silico Exploration of the Kidney Rho-GTPase System Regulation in CKD

Identifying and Clustering CKD Progression Trajectories Using Machine Learning

Reduction in Proximal Tubular Secretion Precedes Reduction in Glomerular Filtration Rate in the Adenine-Induced CKD Model

Prevalence of diabetes, hypertension, anemia and hyperkalemia as frequent comorbidities in patients with chronic kidney disease regardless of their KDIGO staging

Development of a Global Chronic Kidney Disease-Personal Impact Index (CKD-PII) Assessing the Reality of Living with CKD

 

Defining the Excess Risk of Adverse Kidney Outcomes in CKD Patients with Type 2 Diabetes in the DISCOVER-CKD Cohort

Characteristics of CKD Patients with Hyperkalemia: A Report from the DISCOVER CKD Retrospective Cohort

Treatment Pathways of Non-Dialysis-Dependent CKD Patients with Anemia: A Report from the DISCOVER CKD Retrospective Cohort

Clinical Characteristics and eGFR and Urine Albumin-to-Creatinine Ratio Distribution According to the 2012 KDIGO CKD Classification: A Report from the DISCOVER CKD International Retrospective Cohort

Baseline Characteristics of Non-Dialysis CKD Patients with and Without Anemia: A Report from the Retrospective Cohort from DISCOVER CKD

Healthcare Resource Utilisation and Costs of CKD According to the 2012 KDIGO CKD Classification: A Report from the DISCOVER CKD Retrospective Cohort

Treatment Pathways of CKD Patients Defined by the 2012 KDIGO CKD Classification: A Report from the DISCOVER CKD Retrospective Cohort

Treatment Pathways of Patients with CKD: A Report from the DISCOVER CKD Retrospective Cohort

Impact of Renal Impairment and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat

A Marginal Structural Model to Estimate Causal Effect of Time-Dependent Anemia Status on Renal and Cardiovascular Outcomes Among Community-Dwelling Japanese Subjects at Beginning of Impaired Renal Function

Roxadustat Treatment of Anemia in Non-Dialysis-Dependent CKD Is Not Influenced by Iron Status

Roxadustat Lowers Risk of RBC Transfusion in Patients with Anemia in CKD

Roxadustat vs. Placebo or Epoetin Alfa Has No Clinically Meaningful Effect on Blood Pressure in Patients with Anemia of CKD

Hemoglobin (Hb) Correction with Roxadustat is Associated with Improved Iron Homeostasis in Patients with Non-Dialysis-Dependent CKD (NDD-CKD)

Hemoglobin (Hb) correction with roxadustat is associated with improved iron homeostasis in patients with dialysis-dependent CKD (DD-CKD)

Roxadustat Increases Hemoglobin in Anemic Dialysis-Dependent (DD) CKD Patients Independent of Inflammation

Effects of Roxadustat Treatment on Serum Parathyroid Hormone (PTH) in Hemodialysis Patients with Erythropoiesis-Stimulating Agent (ESA) Resistant Anemia

Roxadustat treatment results in consistent improvements in hemoglobin (Hb) versus placebo: an analysis of 3 multinational RCTs in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD)

Roxadustat treatment corrects anemia to hemoglobin (Hb) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD)

Roxadustat Increases Hemoglobin in Anemic Non-Dialysis-Dependent (NDD) Chronic Kidney Disease (CKD) Patients Independent of Inflammation

Pooled Analyses of the Phase 3 Roxadustat Studies: Congestive Heart Failure Hospitalization Rates in Dialysis and Non-Dialysis Patients with Anemia treated with Roxadustat versus Comparators

Roxadustat Favorably Modifies Iron Indices in Patients with Non–dialysis-dependent Chronic Kidney Disease-related Anemia

Efficacy and Safety of Roxadustat in Patients with Dialysis-Dependent CKD, Anemia, and Diabetes Mellitus

Efficacy and Safety of Roxadustat in Patients with Dialysis-dependent Chronic Kidney Disease and Anemia on Hemodialysis

Efficacy and Safety of Roxadustat in Patients with Dialysis-dependent Chronic Kidney Disease and Anemia on Peritoneal Dialysis

Subgroup Analyses of Efficacy of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD

Efficacy and Safety of Roxadustat in Patients with Non–dialysis-dependent CKD, Anemia, and Diabetes Mellitus

A Phase 3, Multicenter, Randomized, Open-label, Active Comparator Conversion Study of Roxadustat in Non–Dialysis-Dependent (NDD) Patients with Anemia in Chronic Kidney Disease (CKD)

Ophthalmological Effects of Roxadustat in the Treatment of Anemia in Dialysis-Dependent and Non–Dialysis-Dependent Chronic Kidney Disease Patients: Findings From Two Phase 3 Studies

Risk of Transfusion in Patients with Dialysis-Dependent Chronic Kidney Disease Increases with Hemoglobin Levels <10 g/dL vs. ≥10 g/dL: Pooled Results from Roxadustat Phase 3 Studies 

Cost and Healthcare Resource Use in Patients with Anemia in CKD Using Linked US Claims and Electronic Health Records

Patient Preferences Study for Treatment of Anemia in CKD Patients Not on Dialysis (NDD)

Rates of Clinical Events in Patients with CKD: A UK Population-Based Cohort Study

A Real World Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent Chronic Kidney Disease Patients, a CKDopps Study

Role of Roxadustat in Improving Erythropoiesis-Stimulating Agent (ESA)-Resistant Anemia in Patients on Maintenance Hemodialysis

Understanding Treatment of Severe Anemia due to Chronic Kidney Disease: A Descriptive Study in Non-Dialysis MAPD Patients

Efficacy and Safety of Roxadustat in Patients with Dialysis-dependent CKD, Anemia, and Heart Failure

Prevalence of Severe Anemia and Transfusion Risk in Medicare and Non-Medicare Populations with CKD Stages 3 and 4

Roxadustat for the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis (NDD): A Phase 3, Randomized, Open-Label, Active-Controlled Study

Clinical Outcomes in Patients with Anemia in CKD Using Linked US Claims and Electronic Health Records

Adverse Event Rates are Higher Post-transfusion vs. Overall Follow-up and Independent of Background Anemia Treatment in Patients with Chronic Kidney Disease

Efficacy and Safety of Roxadustat in Patients with Non-Dialysis-Dependent CKD, Anemia, and Heart Failure

Risk of Transfusion in Patients with Non–dialysis-dependent CKD Increases with Hemoglobin Levels <10 g/dL vs. ≥10 g/dL: Pooled Results from Roxadustat Phase 3 Studies

Health-related Quality of Life in Roxadustat-treated Patients with Anemia and Non–dialysis-dependent CKD

Roxadustat Lowers Low-Density Lipoprotein Cholesterol in Patients with Anemia of CKD

Roxadustat Is Not Associated with An Increased Risk of Neoplasm in Patients with Chronic Kidney Disease and Anemia

Subgroup Analyses of Efficacy of Roxadustat for Treatment of Anemia in Patients with Incident Dialysis-Dependent CKD

Late-Breaking Clinical Trial: Associations Between Achieved Hemoglobin and Cardiovascular Outcomes in the Pooled Phase 3 Trials of Roxadustat in Dialysis-Dependent Patients with Anemia of CKD

Prevalence and Severity of Anemia Between Non-Dialysis and Dialysis Outpatients Referred to Nephrology Consultation: Epidemiologic Data from 1568 Mexican Patients at a National Reference Hospital

Late-Breaking Clinical Trial: Associations Between Achieved Hemoglobin and Cardiovascular Outcomes in the Pooled Phase 3 Roxadustat Studies of Non-Dialysis-Dependent Patients with Anemia of CKD

Prevalence and Severity of Hyperkalemia in Patients Referred to Nephrology Consultation: Epidemiologic Data from 1106 Mexican Patients at a National Reference Hospital

Hyperkalaemia Risk and Mortality in Patients with Diabetes

Risk of Hypokalemia in Hyperkalemic Hemodialysis Patients

Course of Hyperkalemia in Patients on Hemodialysis

Post-discharge outcomes among hyperkalemic patients treated with and without SPS in the inpatient setting

The Relationship Between Comorbidities and Hyperkalaemia in Patients with CKD

Relationships Between CKD Duration, Serum Potassium Level, and Adverse Outcomes

Machine Learning Models for Risk Prediction of Adverse Events in Hyperkalemic Patients

Patient and Clinician Preferences for Hyperkalemia Treatment: A Qualitative Study

Patient Palatability and Preference Study of Three Potassium Binders in Patients with CKD and Hyperkalemia: Rationale and Design of the APPETIZE Study

Time to Hyperkalemia Recurrence in 1 Year Among 103,155 US Veterans

The DAPA-CKD-Like Population in a Contemporary US Healthcare System: Cohort Characteristics and Clinical Outcomes

Healthcare Resource Utilization and Costs in a DAPA-CKD-Like Population Using a Contemporary US Healthcare Cohort

Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with CKD (DIAMOND): A Randomized Double-Blind Cross-Over Trial

The Impact of Decline in Renal Function on the Clinical and Economic Burden of CKD:An Application of the DAPA-CKD Cost-Effectiveness Model

Lower Cardiorenal Risk with SGLT2 Inhibitor vs. DPP4 Inhibitor in Type 2 Diabetes Patients Without Established Cardiovascular and Renal Diseases

Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analysis from DECLARE-TIMI 58 Trial

Renal Outcomes and All-Cause Death Associated with SGLT-2 Inhibitor vs. Other Glucose-Lowering Drugs (CVD-REAL 3 Korea)

Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist, for Patients with Type 2 Diabetes Mellitus and CKD

Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis

Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis

Estimating the Future Burden of CKD Through Microsimulation Methods

Treatment for Chronic Kidney Disease: A Systematic Literature Review and Population Comparison 

Dapagliflozin Reduces the Risk of Hyperkalemia in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis DAPA-HF

Effects of Dapagliflozin on Kidney Function, Cardiovascular Events and All-Cause Mortality According to Cause of Kidney Disease in the DAPA-CKD Trial 

Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis

Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist, for Patients with Type 2 Diabetes Mellitus and CKD

During P2Y12 Antiplatelet Therapy, Treatment of Anemia Was More Frequent Among Peripheral Artery Disease Patients with Lower eGFR: The EUCLID Trial